The data presented here also clearly demonstrated that the thioredoxin-targeted nanodevice can be used in a functional assay to identify reactive stroma in prostate cancer, providing strong support for the hypothesis that an ROS and/or RNS producing inflammatory response is associated with PCA and distinct from BPH. The gene discussed is TXN; the disease is benign prostatic hyperplasia.